El medicamento para el cáncer de Novartis se aprobó con un precio de US$475.000

The transcript discusses CAR T therapy, a pioneering cancer treatment and the first gene therapy approved in the US. It highlights Gilead's acquisition of Kite Pharma and the potential approval of another CAR T drug. The discussion also covers the high cost of these therapies, with expectations that prices may decrease as usage increases and competition grows.

What is significant about CAR T therapy in the context of gene therapies?

• It is the most expensive therapy ever.

• It is the only therapy for all types of cancer.

• It was developed by Kite Pharma alone.

• It is the first gene therapy approved in the US.

What is expected to happen by the end of November regarding CAR T therapies?

• All CAR T therapies will be withdrawn.

• A new CAR T therapy might be approved.

• The price of CAR T therapies will double.

• CAR T therapies will be available worldwide.

How many CAR T therapies are currently being studied?

• None

• Exactly 1000

• More than 500

• Less than 100

What is a potential reason for the high initial cost of CAR T therapies?

• High production costs

• Excessive marketing

• Limited availability of raw materials

• Lack of competition

What could lead to a decrease in the price of CAR T therapies?

• Government subsidies

• Reduction in research funding

• Increased usage and competition

• Decrease in demand